Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: Relationship to dementia and hallucinations

Movement Disorders

Volumn 20, Issue 8, 2005, Pages 989-994

  Camicioli, Richard ^a,d   Rajput, Ali ^b   Rajput, Michelle ^b   Reece, Christian ^a   Payami, Haydeh ^c   Hao, Chunhai ^a   Rajput, Alex ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c WADSWORTH CENTER   (United States)

^d GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

Apolipoprotein E; Cathechol O methyltransferase; Dementia; Hallucinations; Parkinson's disease

Indexed keywords

APOLIPOPROTEIN E4; CATECHOL METHYLTRANSFERASE; APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN TISSUE; CONTROLLED STUDY; DEATH; DEMENTIA; FEMALE; GENOTYPE; HALLUCINATION; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; MEDICAL RECORD; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SURVIVAL; BRAIN CORTEX; CADAVER; COMPARATIVE STUDY; DEMOGRAPHY; GENE FREQUENCY; GENETICS; METHODOLOGY; PATHOLOGY; PROSPECTIVE STUDY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; AUTOPSY; CATECHOL O-METHYLTRANSFERASE; CEREBRAL CORTEX; DEMENTIA; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENOTYPE; HALLUCINATIONS; HUMANS; LEWY BODIES; MALE; PARKINSON DISEASE; POSTMORTEM CHANGES; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 26444534522     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20481     Document Type: Article

References (43)

1. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123(Pt 4):733-745.
2. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-2082.
3. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
4. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
6. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson disease. Arch Neurol 1997;54:260-264.
7. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60: 1756-1761.
8. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601.
9. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
10. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
11. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
12. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
13. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, et al. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003;74:720-724.
14. Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 2004;31:7-21.
15. Zareparsi S, Camicioli R, Sexton G, et al. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet 2002;107:156-161.
16. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002;70:985-993.
17. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79:458-461.
18. Harhangi BS, de Rijk MC, van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54:1272-1276.
19. de la Fuente-Fernandez R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol 1999;22: 226-230.
20. Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 2001;58:209-213.
21. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991;18: 275-278.
22. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57: 1497-1499.
23. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
24. Mattila PM, Koskela T, Roytta M, et al. Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology. Acta Neuropathol (Berl) 1998; 96:417-420.
25. Arendt T, Schindler C, Bruckner MK, et al. Plastic nouronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 1997;17:516-529.
26. Zhu BT. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002;3:321-349.
27. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17:289-296.
28. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
29. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997; 57:5493-5497.
30. Egensperger R, Bancher C, Kosel S, et al. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun 1996;224:484-486.
31. Mattila PM, Rinne JO, Helenius H, et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000; 100:285-290.
32. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl) 2003;106:83-88.
33. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinsons disease. J Neurol Neurosurg Psychiatry 2003;74:852-856.
34. Inzelberg R, Paleacu D, Chapman J, Korczyn AD. Re: The apolipoprotein E epsilon4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol 2000; 23:230-231.
35. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602.
36. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000;55: 539-544.
37. Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000;23:143-148.
38. Lee MS, Lyoo CH, Ulmanen I, et al. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001;298:131-134.
39. Akil M, Kolachana BS, Rothmond DA, et al. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003;23:2008-2013.
40. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-6922.
41. Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19:885-891.
42. Jellinger K. The association of incident dementia with mortality in PD. Neurology 2003;61:424.
43. Fall PA, Saleh A, Fredrickson M, et al. Survival time, modality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18:1312-1316.